Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06415799 · ClinicalTrials.gov registry record

OM2 Abbreviated Sensor Verification

A clinical trial of Hypoxia, sponsored by Medtronic - MITG.

Completed
Registry status
28
Enrollment target
1
Study location

NCT06415799: Completed study of Hypoxia, sponsored by Medtronic - MITG.

NCT06415799 is a study of Hypoxia that has completed, run by Medtronic - MITG. The registered enrollment target is 28 participants, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06415799, a study of Hypoxia, has completed, sponsored by Medtronic - MITG.

COMPLETED
Registry status
28 participants
Enrollment target
1
Study location

Study Summary

The verification of an investigational pulse oximetry board to verify pulse rate and saturation accuracy over a specified saturation range in diverse populations.

Primary Outcome

Acceptance criteria for * SpO2 across the saturation range of 70-100% * Pulse rate from 20-250 BPM

Conditions Studied

Study Locations (1)

Colorado

  • Element - Louisville

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2024-02-11
Est. Completion 2024-02-22
Medtronic - MITG

119 total trials

What the finished NCT06415799 record still lists

NCT06415799 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hypoxia appearing as the primary indexed condition, and to 0 interventions.

NCT06415799 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT06415799 about?

NCT06415799 is a clinical study titled "OM2 Abbreviated Sensor Verification". The verification of an investigational pulse oximetry board to verify pulse rate and saturation accuracy over a specified saturation range in diverse populations.

What is the current status of trial NCT06415799?

This trial is currently completed. The enrollment target is 28 participants. The study started on 2024-02-11. Estimated completion is 2024-02-22.

What conditions does trial NCT06415799 study?

This clinical trial studies the following conditions: Hypoxia.

Who is sponsoring clinical trial NCT06415799?

This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06415799 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypoxia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06415799's enrollment target sits among peer trials

28 22nd of 39 higher than 18 of 39 other Hypoxia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypoxia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06415799, the US trial registry maintained by the National Library of Medicine. NCT06415799 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.